SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
Materials and resources for healthcare professionals:
F508del Homozygous Clinical Trial Overview Brochure
Review information about patients with CF who are homozygous for the F508del mutation.
Review information about efficacy, safety, DDIs, dosing and new clinical trial data for patients age 6 through 11.
Review considerations for initiating SYMDEKO.
See all indicated mutations for SYMDEKO.